A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the BreastLawrence J. Solin, S Badve, Nancy E. Davidson et al.|JNCI Journal of the National Cancer Institute|2013Cited by 523
Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation studyRoger J. Laham, Michael Simons, Nicholas Chronos et al.|Journal of the American College of Cardiology|2000Cited by 223
Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 Improves Stress and Rest Myocardial Perfusion Abnormalities in Patients With Severe Symptomatic Chronic Coronary Artery DiseaseJames E. Udelson, Michael Simons, Vasken Dilsizian et al.|Circulation|2000Cited by 163
Pharmacokinetics and Pharmacodynamics of Recombinant FGF‐2 in a Phase I Trial in Coronary Artery DiseaseMark Bush, Nicolas A.F. Chronos, Marilyn C. Pike et al.|The Journal of Clinical Pharmacology|2001Cited by 48
Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast CancerVered Stearns, Nancy E. Davidson, Lisa K. Jacobs et al.|Clinical Cancer Research|2013Cited by 27